Mar 30, 2023
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer
Mar 22, 2023
Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023
Mar 13, 2023
Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer
Feb 06, 2023
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
Jan 29, 2023
Immutep Quarterly Activities Report
